Is Mesoblast limited worth a closer look today?

Shares of Mesoblast limited (ASX: MSB) were savaged on Monday following a very disappointing float on the NASDAQ exchange in the United States.

Following a two-week suspension from trading, the shares fell more than 38%, sliding from $3.41 to close at just $2.10 with founder and CEO Silviu Itescu reportedly losing nearly $90 million in the process, according to The Australian Financial Review. That compares to a 0.9% fall for the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO), making it by far the worst performing stock for the day.

Source: ASX

Source: ASX

Indeed, there are numerous advantages to having a dual-listing in the US, including having access to one of the biggest pool of investors in the world. What’s more, the United States has a deep understanding of the biotechnology and healthcare sectors which should be a positive for the group.

However, the float was by no means a success. Where the company had hoped to sell American Depositary Shares (ADSs) for US$12.10 each (where each ADS was equivalent to five Australian shares), they sold for just US$8 which implies a market value of just $2.20 in terms of Australian dollars. The issue represented 12.6% of Mesoblast’s issued capital.

Despite the disappointing float, the company still expects gross proceeds of AU$95.8 million. Indeed, companies in the biotech sector are generally capital intensive in nature with the proceeds to go towards ongoing clinical programs, research and development expenses, commercial manufacturing requirements as well as general and administrative purposes.

Even at its beaten-down share price, Mesoblast is by no means a risk-free investment. Biotechs tend to burn through cash very quickly while recognising very little (if any) revenue, so further capital raisings are possible in the future. Still, the heavy fall could be an opportunity for long-term investors to take a closer look at the company and its potential.

What would YOU do if the market crashed tomorrow?

Discover our Foolish experts' advice on what YOU should do in the event of a crisis -- simply click here for your FREE copy of our newly updated report, "What to Do When the Sharemarket Crashes". Click here, it's FREE!.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can follow Ryan on Twitter @ASXvalueinvest.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.